INTRODUCTION
Endothelin (ET), a 21 amino acid peptide with potent vasoconstrictor properties, was described in 1988 by Yanagisawa et al. (28) and subsequently found to comprise a family of pharmacologically distinct isoforms, ET-1, ET-2 and ET-3 (11). Two receptors for ET, ET-A and ET-B have been identified and cloned (14) . The ET-A receptor is highly specific for ET-1 and is widely distributed in vascular smooth muscle cells. ET-1 stimulation of the ET-A receptor mediates most of the vasoconstrictor response to ET (6, 14, 21) . The ET-B receptor, unlike ET-A, responds equally to all three isoforms of ET, is present largely on endothelial cells and mediates endothelium-dependent vasodilation by stimulating NO formation (6,14).
In contrast to endothelin, the production of nitric oxide (NO) by endothelial cells plays an important role in inducing smooth muscle relaxation. Inhibition of NO production in vivo using analogues of arginine such as Nco-nitro-L-arginine methyl ester (L-NAME) results in a substantial increase in blood pressure and a fall in renal blood flow and GFR (3, 9, 19, 22) . These studies indicate that the constitutive production of NO contibutes to the modulation of basal vascular tone in the resistance vessels of the kidney and other organs and plays an essential role in the regulation of blood pressure and renal function.
It has become evident that a complex counterregulatory relationship exists between NO and endothelin. NO not only opposes ET action by independently causing vasodilation (19), but also plays an important role in directly modulating the production and vasoconstrictor effects of ET-1. NO, produced by endothelium or provided exogenously by NO donors such as sodium nitroprusside, inhibits the production of endothelin by endothelial cells at a transcriptional level (5,15). If NO plays an important role in negatively modulating ET-1 production and activity, a reduction in NO availability would be expected to increase ET-1 production and/or activity which in turn should contribute additively to the vasoconstrictor effects associated with a reduction in NO production. We have shown, using an inhibitor of the ET-A receptor, that ET-1 contributes to the systemic and intrarenal hemodynamic effects induced by L-NAME in pentobarbitai anesthetized rats.
METHODS

Surgical procedures:
Male Sprague-Dawley rats, weighing between 300 and 350g fed regular Purina rat chow (Purina Mills, Chicago, IL) and allowed free access to water were used for all experiments. Rats were anesthetized with an intraperitoneal injection of pentobarbitai sodium (5 mg/100g body wt) followed by a constant intravenous infusion of pentobarbitai sodium (91 ug/min) as previously described Cardiac output (CO) was measured using the thermodilution method. The accuracy and reliability of this technique for measuring CO is well established (8).
The determination of CO was performed by a Cardiomax ll-R computor (Columbus Instruments Corp., Columbus, OH.) as previously described (24) . Briefly, CO was with L-NAME (n=12).
Baseline period: After preparation of the rats as outlined above, an infusion of inulin and PAH was begun. After an equilibration period of 30 min, three 15 minute urine collections were obtained for measurement of baseline inulin and PAH clearance. MAP and heart rate were monitored continuously throughout this period.
L-NAME period: At the end of the baseline period a constant infusion of L-NAME (0.12mg/kg/min) was begun and continued until the end of the experiment. After a 30 minute equilibration period, three 15 minute collections of urine were obtained for determination of inulin and PAH clearances as well as MAP and heart rate.
L-NAME + BQ610 period: A bolus of 100ug/kg of BQ610 was administered slowly, followed by a constant infusion of BQ610 (4ug/kg/min) which was continued for the duration of the experiment. After a further 30 minute equilibration period, three 15 minute clearance periods were obtained for clearance measurements, MAP and heart rate.
Duplicate determinations of cardiac output, were made during the baseline, L-NAME and L-NAME + BQ periods and the duplicate results averaged. The measurements of GFR and effective renal plasma flow obtained during the three clearance periods were also averaged.
b^ Control protocols i) Effect of BQ610 following administration of the L-NAME vehicle (n=5^
The protocol for this study was identical to the experimental protocol except that the vehicle for L-NAME (5g/100ml dextrose water infused at a rate of 0.01m!/min) was given instead of L-NAME. The purpose of this protocol was to determine if ET-A blockade altered systemic or renal resistance in the absence of prior NO inhibition with L-NAME.
in Effect of BQ vehicle following L-NAME fn=4)
This protocol was the same as the experimental protocol except that the vehicle for BQ610 (bolus of 250ul of normal saline followed by a constant infusion of normal saline infused at 0.01ml/min) was given after L-NAME instead of the BQ610. The purpose of this protocol was to provide a time control for the effects of L-NAME infusion. The extent (in %) to which blockade of the ET-A receptor by BQ610 reversed the changes in MAP, CO, SVR and RVR induced by L-NAME was calculated as follows:
i) Fall in MAP (%): (MAP during L-NAME period) -(MAP during BQ610+L-NAME period) divided by (MAP during L-NAME period) -(MAP during baseline period) X 100
ii) Fall in SVR (%): (SVR during L-NAME period) -(SVR during BQ610+L-NAME period) divided by (SVR during L-NAME period) -(SVR during baseline period) X 100
Hi) Fall in RVR (%): (RVR during L-NAME period) -(RVR during BQ610+L-NAME period) divided by (RVR during L-NAME period) -(RVR during baseline period) X 100 iv) Increase in CO (%): (CO during BQ610 period) -(CO during L-NAME period)
divided by (CO during baseline period) -(CO during L-NAME period) X 100 4) Statistics: All data are expressed as means ± SE. All comparisons were made using the Student's t test. Whenever more than two groups of data were compared the Bonferroni correction was used to adjust for the comparison of multiple means.
RESULTS
1.Efficacy of BQ610 in antagonizing the hypertensive effect of ET-1
In rats administered endothelin following administration of the BQ610 vehicle, MAP rose from 107±3 to 135±1mmHg (p<0.01)(n=4). In rats pretreated with BQ610, the administration of endothelin thirty minutes later increased MAP from 110±4 to 113±3 mmHg (p<0.01). Thus, BQ610 resulted in an 91% reduction in the ET-1 induced increase in MAP (p<0.01 vs endothelin in the abence of BQ610 pre-treatment).
2. Effect of BQ610 on the systemic and renal hemodvnamic effects of L-NAME MAP rose from 107+2 (baseline period) to 133±3mmHg following infusion "of L-NAME (p<0.01). Subsequent infusion of BQ610 resulted in a fall in MAP to 115±3mmHg (p<0.01 vs baseline and L-NAME periods) (Figure 1 ). Cardiac output fell from 90+5 to 66±5ml/min/300g with L-NAME and then increased to 71±5ml/min/300g after BQ610 (p<0.01 vs baseline as well as L-NAME periods)( Figure   1 ). Stroke volume fell with L-NAME from 260±13ml to 201 ±14 ml/beat/300g(p<0.01) and remained unchanged during endothelin blockade with BQ610 (196±11 ml/beat/300g) (p=NS vs L-name period; p<0.01 vs baseline period). Heart rate fell from 350±11 to 320±6 beats/min with L-NAME (p<0.01) and returned to values comparable to control (348±10 beats/min) with BQ610 (p<0.01 compared to L-NAME period). Systemic vascular resistance rose from 1.27±0.06 to 2.17±0.18 mmHg/ml/min/300g in response to L-NAME (p<0.01) and fell to 1.69+0.12 mmHg/ml.min/300g after BQ610 (p<0.01 vs L-NAME and baseline periods) (Figure 1 ).
GFR fell from 3.0±0.2 to 2.6±0.2ml/min/300g with L-NAME (p<0.01) but remained unchanged (2.6±0.1ml/min/300g) following BQ610 (Figure 2 ). The filtration fraction rose from 32.0±1.0 to 45.0+2.0% (p<0.01) but was unaltered by BQ610 (45±3.0%). Urine flow rate rose from 10±3 to 44±9ul/min with L-NAME (p<0.01) and then fell to 25±4ul/min following BQ610 (p<0.01 compared to baseline and L-NAME periods). RPF fell following L-NAME from 9.5±0.6 to 5.9±0.6 ml/min/300g (p<0.01) while RBF (Figure 2 ) fell from 17.1±1.2 to 10.8±0.9 ml/min/300g (p<0.01). BQ610 did not alter either RPF (6.3±0.5ml/min/300g) or RBF (0.8±0.9ml/min.300g) (Figure 2 ).
Renal vascular resistance rose from 6.4±0.4 to 13.7±1.4 mmHg/ml/min/300g with L-NAME (P<0.01) and then fell to 11.0±0.9 mmHg/ml/min/300g following BQ610 (P<0.01
compared to baseline and L-NAME periods) (Figure 2 ).
The proportion of the alterations in MAP, SVR and cardiac output induced by L-NAME that were reversed by BQ610 were calculated as described in the methods section. The BQ610 induced reversal of the L-NAME induced rise in SVR (52+7%) was substantially greater than the reversal of the L-NAME induced fall in cardiac output (31±9%) associated with ET-A blockade (p<0.05) (Figure 3) . As a result, BQ610
reversed the L-NAME associated hypertension to a proportionately greater extent (76±10%) than the L-NAME associated increase in SVR (p<0.01) (Figure 3) . BQ610
reversed the L-NAME induced increases in SVR (by 52±7%) and RVR (by 40±9%) to a comparable extent.
3. Effect of BQ610 on systemic and renal hemodvnamic effects when administered in the absence of prior L-NAME infusion.
Systemic and renal hemodynamics as well as renal function were unchanged when BQ610 was administered following administration of the L-NAME vehicle (Table   1 ).
Effect of the BQ610 vehicle following administration of L-NAME
When L-NAME infusion was followed by administration of the BQ610 vehicle, the systemic and renal hemodynamic alterations induced by L-NAME remained unchanged (Table 2) .'
DISCUSSION
The systemic and renal effects of NO synthase inhibition reported in this study were comparable to those reported in many other studies conducted in vivo in both conscious (3,9) and anesthetized animals (1, 22, 20, 23) .
L-NAME caused systemic vasoconstriction, increasing total peripheral resistance and markedly elevating MAP into the hypertensive range (Figure 1 ).
However, the MAP did not increase in proportion to the increase in peripheral resistance because of an associated profound fall in cardiac output (Figure 1 ) that was due to a decrease in both stroke volume and heart rate. Comparable changes in cardiac output, stroke volume and heart rate have been previously reported in response to L-NAME in conscious rats (9). The fall in heart rate in response to NO inhibition has been ascribed to a reflex baroreceptor response to the hypertension (1,9,23). The factor/s responsible for the substantial fall in stroke volume are less certain since the effects of NO on myocardial function remain incompletely understood and controversial (9,17). In addition to its systemic effects, L-NAME In the absence of prior NO inhibition, BQ610 had no effects on renal or systemic hemodynamics (Table 1) suggesting than ET, acting via »the ET-A receptor, does not substantially modulate renal or systemic hemodynamics in the euvolemic rat. Also, administration of the BQ610 vehicle after NO inhibition did not alter the systemic or renal hemodynamic changes induced by L-NAME (Table 2 ).
However, ET-A blockade with BQ610 had marked effects on systemic and renal hemodynamics when administered after L-NAME. BQ610 resulted in a substantial fall in the L-NAME induced increase in both MAP and SVR (Figure 1 ). These data indicate for the first time that endothelin, acting via the ET-A receptor, contributes to the systemic vasoconstriction induced by NO inhibition.
Interestingly, the fall in MAP associated with BQ610 was proportionately greater than the reduction in systemic vascular resistance (SVR) (Figure 3 ) because cardiac output did not increase in proportion to the fall in SVR following ET-A receptor blockade (Figure 3 ). The increase in cardiac output following BQ610 was due entirely to a reversal of the reflex fall in heart rate induced by L-NAME while the depression in stroke volume was unchanged by ET-A receptor blockade. These data suggest that the fall in stroke volume induced by L-NAME, unlike the peripheral vascular constriction, is mediated by mechanisms independent of ET acting via the ETA receptor.
BQ610 also resulted in a fall in renal vascular resistance (RVR) (Figure 2) suggesting that ET-1 induced vasoconstriction contributes substantially to the intrarenal vasoconstriction associated with L-NAME. The extent to which BQ610 reduced the L-NAME induced increases in RVR (40+9%) and SVR was comparable (52±7%). However, we cannot determine the extent to which changes in RVR in response to BQ610 are due to direct effects of ET-A blockade versus a reflex aatoregulatory response to the BQ610 associated fall in blood pressure (2).
Recent The effect of L-NAME followed bv BQ61Q on mean arterial pressure cardiac output and systemic vascular resistance (n=12) *=p<0.01 compared to baseline period; f=p<0.01 compared to L-NAME period
Figure 2
Effect of L-NAME followed bv BQ610 on alomerular filtration, renal blood flow and renal vascular resistance (n=12) *=p<0.01 compared to baseline period; t=P<0.01 compared to L-NAME period Figure 3 Proportion of the L-NAME induced changes in MAP. SVR and CO that were reversed bv ET-A receptor blockade.
The L-NAME increase in SVR was reversed by BQ610 to a greater extent than the L-NAME associated fall in CO . As a results fall in MAP was substantially greater than the fall in SVR induced by BQ610. 
